goralatide has been researched along with Disease Models, Animal in 30 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (20.00) | 29.6817 |
| 2010's | 20 (66.67) | 24.3611 |
| 2020's | 4 (13.33) | 2.80 |
| Authors | Studies |
|---|---|
| Abrams, RPM; Bachani, M; Balasubramanian, A; Brimacombe, K; Dorjsuren, D; Eastman, RT; Hall, MD; Jadhav, A; Lee, MH; Li, W; Malik, N; Nath, A; Padmanabhan, R; Simeonov, A; Steiner, JP; Teramoto, T; Yasgar, A; Zakharov, AV | 1 |
| Deng, HJ; Gong, HB; Gong, RB; Miao, ZY; Tang, XY; Zhang, CM | 1 |
| Balalaie, S; Kamarehei, M; Pejman, S; Pooyan, S; Riazi, G | 1 |
| Goodwin, JE; Kanasaki, K; Koya, D; Srivastava, SP | 1 |
| Carretero, OA; Kumar, N; Liao, TD; Maheshwari, M; Monu, SR; Peterson, EL; Romero, CA | 1 |
| Attwood, KM; Dahal, S; Nguyen, J; Pokharel, S; Sexton, S; Sharma, UC; Singh, AK; Sonkawade, SD; Spernyak, JA; van Berlo, JH | 1 |
| Carretero, OA; Kumar, N; Liao, TD; Nakagawa, P; Peterson, EL; Romero, CA; Worou, ME | 1 |
| Dan, L; Dingjie, X; Fang, Y; Guizhen, Z; Hong, X; Lijuan, Z; Qiaodan, Z; Ruimin, W; Shifeng, L; Siyu, N; Wenchen, C; Xue, Y; Xuemin, G; Zhongqiu, W | 1 |
| Hao, Q; He, L; Li, M; Li, W; Pang, Z; Wang, Z; Xu, C; Zhang, C; Zhang, W; Zhang, X; Zhang, Y; Zhou, J; Zhu, Y | 1 |
| Gao, X; Li, S; Wang, R; Wei, Z; Xu, D; Xu, H; Yang, F; Yi, X; Zhang, B; Zhang, G; Zhang, H; Zhang, L; Zhang, X; Zhang, Y; Zhu, Y | 1 |
| Brolin, TJ; Carretero, OA; Chun, B; Fogo, AB; Kazi, N; Kon, V; Ma, LJ; Myöhänen, T; Orhan, D; Potthoff, SA; Rhaleb, NE; Yang, HC; Zuo, Y | 1 |
| Chopp, M; Ding, G; Jiang, Q; Rhaleb, NE; Teng, H; Yang, XP; Zhang, L; Zhang, ZG | 1 |
| Chopp, M; Ding, G; Jiang, Q; Li, L; Li, Q; Wei, M; Zhang, L; Zhang, Z | 1 |
| Cheng, H; Li, Q; Ma, W; Sun, Y; Wang, R; Wei, Z; Xu, H; Yang, F; Zhang, L | 1 |
| Deng, H; Du, S; Li, S; Sun, Y; Wang, R; Wei, Z; Xu, H; Xue, X; Yang, F; Yuan, Y | 1 |
| Carretero, OA; D'Ambrosio, M; Janic, B; Liao, TD; Nakagawa, P; Peterson, EL; Rhaleb, NE; Worou, ME; Yang, XP | 1 |
| Conte, E; Cuzzocrea, S; Esposito, E; Fagone, E; Fruciano, M; Genovese, T; Gili, E; Iemmolo, M; Vancheri, C | 1 |
| Carretero, OA; D'Ambrosio, M; Janic, B; Liao, TD; Nakagawa, P; Peterson, EL; Rhaleb, NE; Worou, ME | 1 |
| Deng, H; Gao, X; Li, S; Liu, Y; Tian, J; Wang, X; Wei, Z; Xu, D; Xu, H; Yang, F; Zhang, L | 1 |
| Conte, E; Cordaro, M; Cuzzocrea, S; Fagone, E; Fruciano, M; Gili, E; Iemmolo, M; Impellizzeri, D; Pistorio, MP; Vancheri, C | 1 |
| Chan, GCW; Chan, KW; Huang, XR; Lai, KN; Lan, HY; Tang, SCW; Wu, HJ; Yiu, WH; Zou, A | 1 |
| Chopp, M; Mahmood, A; Meng, Y; Xiong, Y; Zhang, L; Zhang, Y; Zhang, ZG | 1 |
| Li, Q; Yan, JB; Zhang, LJ | 1 |
| André, S; Carretero, OA; D'Ambrosio, M; Gabius, HJ; Liao, TD; Liu, YH; Peng, H; Rhaleb, NE; Sharma, U | 1 |
| Fogo, AB; Ma, LJ | 1 |
| Chen, P; Li, DD; Li, Q; Wu, KF; Yan, JB; Yang, F; Zhang, LJ | 1 |
| Jia, X; Liu, R; Mu, S; Wang, M; Xie, R | 1 |
| Bobbitt, KR; Carretero, OA; Chen, X; González, GE; Kedl, R; Liao, TD; Liu, Y; Nakagawa, P; Peterson, EL; Rhaleb, NE; Smolarek, D; Yang, XP | 1 |
| Haneda, M; Inomata, N; Kanasaki, K; Kato, Y; Kojima, R; Koya, D; Omata, M; Sho, R; Taniguchi, H | 1 |
| Carretero, OA; Liao, TD; Peng, H; Peterson, EL; Rhaleb, NE | 1 |
2 review(s) available for goralatide and Disease Models, Animal
| Article | Year |
|---|---|
[Meta-analysis of Ac-SDKP inhibition of Pulmonary fibrosis in animal models].
Topics: Animals; Disease Models, Animal; Fibrosis; Proline; Pulmonary Fibrosis; Rats; Rats, Wistar | 2023 |
PAI-1 and kidney fibrosis.
Topics: Angiotensins; Animals; Chronic Disease; Disease Models, Animal; Fibrosis; Humans; Kidney Diseases; Mice; Oligopeptides; Organ Specificity; Plasminogen Activator Inhibitor 1; Renin-Angiotensin System; Thymosin; Transforming Growth Factor beta1 | 2009 |
28 other study(ies) available for goralatide and Disease Models, Animal
| Article | Year |
|---|---|
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Drug Evaluation, Preclinical; High-Throughput Screening Assays; Immunocompetence; Inhibitory Concentration 50; Methacycline; Mice, Inbred C57BL; Protease Inhibitors; Quantitative Structure-Activity Relationship; Small Molecule Libraries; Vero Cells; Zika Virus; Zika Virus Infection | 2020 |
Ac-SDKP ameliorates the progression of experimental autoimmune encephalomyelitis via inhibition of ER stress and oxidative stress in the hippocampus of C57BL/6 mice.
Topics: Animals; Antioxidants; Apoptosis; Caspase 12; Cytokines; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; Endoplasmic Reticulum; Endoplasmic Reticulum Stress; Female; Hippocampus; Inflammation; Male; Mice; Mice, Inbred C57BL; Multiple Sclerosis; Myelin-Oligodendrocyte Glycoprotein; Neurodegenerative Diseases; Oligopeptides; Oxidation-Reduction; Oxidative Stress; Protein Disulfide-Isomerases; Transcription Factor CHOP | 2020 |
Inhibition of Angiotensin-Converting Enzyme Ameliorates Renal Fibrosis by Mitigating DPP-4 Level and Restoring Antifibrotic MicroRNAs.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Cell Line; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Dipeptidyl Peptidase 4; Disease Models, Animal; Drug Synergism; Gene Expression Regulation; Humans; Mice; MicroRNAs; Oligopeptides; Signal Transduction; Transforming Growth Factor beta | 2020 |
Renal Protective Effects of N-Acetyl-Seryl-Aspartyl-Lysyl-Proline (Ac-SDKP) in Obese Rats on a High-Salt Diet.
Topics: Albuminuria; Animals; Anti-Inflammatory Agents; Antihypertensive Agents; Blood Pressure; Disease Models, Animal; Fibrosis; Glomerulonephritis; Hypertension; Kidney; Macrophages; Male; Obesity; Oligopeptides; Rats, Zucker; Sodium Chloride, Dietary | 2018 |
A Small Peptide Ac-SDKP Inhibits Radiation-Induced Cardiomyopathy.
Topics: Animals; Apoptosis; Cardiomyopathies; Cardiotoxicity; Collagen Type I; Collagen Type III; Disease Models, Animal; Extracellular Matrix; Female; Fibrosis; Galectin 3; Macrophages; Magnetic Resonance Imaging; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Myocytes, Cardiac; Oligopeptides; Radiation Injuries; Radiation-Protective Agents; Rats, Sprague-Dawley; RAW 264.7 Cells; Transforming Growth Factor beta1; Ventricular Function, Left | 2018 |
Renal release of N-acetyl-seryl-aspartyl-lysyl-proline is part of an antifibrotic peptidergic system in the kidney.
Topics: Animals; Disease Models, Animal; Fibrosis; Kidney Diseases; Kidney Medulla; Male; Metalloendopeptidases; Nephrons; Oligopeptides; Prolyl Oligopeptidases; Rats, Sprague-Dawley; Serine Endopeptidases; Signal Transduction; Thymosin | 2019 |
Ac-SDKP increases α-TAT 1 and promotes the apoptosis in lung fibroblasts and epithelial cells double-stimulated with TGF-β1 and silica.
Topics: A549 Cells; Acetyltransferases; Animals; Apoptosis; Collagen Type I; Disease Models, Animal; DNA Breaks, Double-Stranded; Epithelial Cells; Fibroblasts; Humans; Lung; Male; Microtubule Proteins; Oligopeptides; Rats, Sprague-Dawley; Signal Transduction; Silicon Dioxide; Silicosis; Transforming Growth Factor beta1; Up-Regulation | 2019 |
d-amino acid modification protects N-Acetyl-seryl-aspartyl-lysyl-proline from physiological hydroxylation and increases its antifibrotic effects on hepatic fibrosis.
Topics: Actins; Amino Acids; Angiotensin-Converting Enzyme Inhibitors; Animals; Carbon Tetrachloride; Cell Proliferation; Chromatography, Liquid; Disease Models, Animal; Hepatic Stellate Cells; Humans; Hydroxylation; Liver; Liver Cirrhosis; Oligopeptides; Peptidyl-Dipeptidase A; Phosphorylation; Protective Agents; Rats; Smad2 Protein | 2019 |
Targeting the RAS axis alleviates silicotic fibrosis and Ang II-induced myofibroblast differentiation via inhibition of the hedgehog signaling pathway.
Topics: Adult; Aged; Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Anthracosis; Captopril; Cell Differentiation; Cell Line; Collagen; Disease Models, Animal; Female; Hedgehog Proteins; Humans; Lung; Male; Middle Aged; Myofibroblasts; Oligopeptides; Peptide Fragments; Pulmonary Fibrosis; Rats, Wistar; Renin-Angiotensin System; Signal Transduction; Silicosis | 2019 |
Thymosin β4 and its degradation product, Ac-SDKP, are novel reparative factors in renal fibrosis.
Topics: Animals; Collagen; Disease Models, Animal; Fibronectins; Fibrosis; Kidney; Kidney Diseases; Macrophages; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Myofibroblasts; Oligopeptides; Plasminogen Activator Inhibitor 1; Prolyl Oligopeptidases; Serine Endopeptidases; Serine Proteinase Inhibitors; Thymosin; Time Factors; Ureteral Obstruction; Urological Agents | 2013 |
Combination treatment with N-acetyl-seryl-aspartyl-lysyl-proline and tissue plasminogen activator provides potent neuroprotection in rats after stroke.
Topics: Animals; Blood-Brain Barrier; Disease Models, Animal; Drug Therapy, Combination; Endothelial Cells; Fibrinolytic Agents; Growth Inhibitors; Humans; Intracranial Embolism; Magnetic Resonance Imaging; Male; Neuroprotective Agents; NF-kappa B; Oligopeptides; Plasminogen Activator Inhibitor 1; Primary Cell Culture; Rats; Rats, Wistar; Stroke; Tissue Plasminogen Activator; Transforming Growth Factor beta1 | 2014 |
MRI evaluation of BBB disruption after adjuvant AcSDKP treatment of stroke with tPA in rat.
Topics: Acute Disease; Animals; Blood-Brain Barrier; Brain; Capillary Permeability; Contrast Media; Disease Models, Animal; Drug Therapy, Combination; Fibrin; Fibrinolytic Agents; Gadolinium DTPA; Immunohistochemistry; Infarction, Middle Cerebral Artery; Longitudinal Studies; Magnetic Resonance Imaging; Male; Neuroprotective Agents; Oligopeptides; Rats, Wistar; Tissue Plasminogen Activator | 2014 |
[Anti-fibrotic role of AcSDKP through inhibition of P38MAPK pathway activity mediated transforming growth beta receptors in rat with silicosis].
Topics: Animals; Cells, Cultured; Collagen; Disease Models, Animal; Fibroblasts; Male; MAP Kinase Signaling System; Oligopeptides; p38 Mitogen-Activated Protein Kinases; Protein Serine-Threonine Kinases; Rats; Rats, Wistar; Receptor, Transforming Growth Factor-beta Type I; Receptor, Transforming Growth Factor-beta Type II; Receptors, Transforming Growth Factor beta; Silicosis; Transforming Growth Factor beta | 2014 |
[Comparative proteomic analysis on anti-fibrotic effect of N-acetyl-seryl-aspartyl-lysyl-proline in rats with silicosis].
Topics: Animals; Disease Models, Animal; Lung; Male; Oligopeptides; Proteome; Rats; Rats, Wistar; Silicosis | 2014 |
N-Acetyl-Seryl-Aspartyl-Lysyl-Proline: mechanisms of renal protection in mouse model of systemic lupus erythematosus.
Topics: Animals; Cell Movement; Complement System Proteins; Cytokines; Disease Models, Animal; Female; Glomerular Filtration Rate; Intercellular Adhesion Molecule-1; Lupus Erythematosus, Systemic; Lupus Nephritis; Mice; Mice, Inbred MRL lpr; Oligopeptides; T-Lymphocytes | 2015 |
Effects of thymosin β4 and its N-terminal fragment Ac-SDKP on TGF-β-treated human lung fibroblasts and in the mouse model of bleomycin-induced lung fibrosis.
Topics: Animals; Anti-Inflammatory Agents; Bleomycin; Cells, Cultured; Disease Models, Animal; Fibroblasts; Humans; Lung; Male; Mice; Oligopeptides; Pneumonia; Protein Structure, Tertiary; Pulmonary Fibrosis; Thymosin; Transforming Growth Factor beta | 2015 |
Renal protective effect of N-acetyl-seryl-aspartyl-lysyl-proline in dahl salt-sensitive rats.
Topics: Animals; Blood Pressure; Disease Models, Animal; Glomerular Filtration Rate; Growth Inhibitors; Hypertension; Kidney; Male; Oligopeptides; Rats; Rats, Inbred Dahl | 2015 |
[Inhibition effect of N-acetyl-seryl-aspartyl-lysyl-proline on myofibroblast differentiation by regulating acetylated tubulin α in silicotic rat model].
Topics: Actins; Animals; Cell Differentiation; Collagen Type I; Disease Models, Animal; Fibroblasts; Lung; Myofibroblasts; Oligopeptides; Rats; Silicon Dioxide; Silicosis; Tubulin | 2015 |
Preventive and therapeutic effects of thymosin β4 N-terminal fragment Ac-SDKP in the bleomycin model of pulmonary fibrosis.
Topics: Actins; Animals; Bleomycin; Chemotaxis, Leukocyte; Collagen; Cytoprotection; Disease Models, Animal; Interleukin-17; Lung; Male; Mice; Myofibroblasts; Oligopeptides; Protective Agents; Pulmonary Edema; Pulmonary Fibrosis; Time Factors; Transforming Growth Factor beta | 2016 |
N-acetyl-seryl-aspartyl-lysyl-proline mediates the anti-fibrotic properties of captopril in unilateral ureteric obstructed BALB/C mice.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Captopril; Disease Models, Animal; Extracellular Matrix Proteins; Fibrosis; Indoles; Kidney; Kidney Diseases; Male; Mice, Inbred BALB C; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Oligopeptides; Peptidyl-Dipeptidase A; Prolyl Oligopeptidases; Serine Endopeptidases; Serine Proteinase Inhibitors; Signal Transduction; Thiazolidines; Transforming Growth Factor beta1; Ureteral Obstruction | 2018 |
Treatment of traumatic brain injury in rats with N-acetyl-seryl-aspartyl-lysyl-proline.
Topics: Angiogenesis Inducing Agents; Animals; Brain; Brain Injuries, Traumatic; Disease Models, Animal; Infusion Pumps; Male; Maze Learning; Neurogenesis; Neurons; Neuroprotective Agents; Oligopeptides; Random Allocation; Rats, Wistar; Recovery of Function | 2017 |
[Anti-fibrotic effect of N-acetyl-seryl-aspartyl-lysyl-proline in lung of rat with silicosis].
Topics: Animals; Collagen; Disease Models, Animal; Drug Antagonism; Lung; Male; Oligopeptides; Pulmonary Fibrosis; Rats; Rats, Wistar; Silicon Dioxide; Silicosis | 2008 |
N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growth-regulatory lectin.
Topics: Animals; Anti-Inflammatory Agents; Blood Pressure; Body Weight; Cardiac Output; Cardiomegaly; Cardiotonic Agents; Collagen; Disease Models, Animal; Echocardiography, Doppler; Fibrosis; Galectin 3; Heart Rate; Hemodynamics; Inflammation; Infusions, Parenteral; Isoproterenol; Macrophages; Male; Mast Cells; Myocardial Contraction; Myocardium; Oligopeptides; Phosphorylation; Rats; Rats, Sprague-Dawley; Signal Transduction; Smad3 Protein; Stroke Volume; Time Factors; Transforming Growth Factor beta; Ventricular Function, Left; Ventricular Remodeling | 2009 |
[Antifibrotic effects of N-acetyl-seryl-aspartyl-lysyl-proline mediated by regulation of transforming growth factor beta and connective tissue growth factor expression on rats with silicosis].
Topics: Animals; Connective Tissue Growth Factor; Disease Models, Animal; Lung; Male; Oligopeptides; Pulmonary Fibrosis; Rats; Rats, Sprague-Dawley; Silicosis; Transforming Growth Factor beta | 2009 |
N-acetyl-seryl-aspartyl-lysyl-proline attenuates renal inflammation and tubulointerstitial fibrosis in rats.
Topics: Animals; Biomarkers; Disease Models, Animal; Fibrosis; Histocytochemistry; Intercellular Signaling Peptides and Proteins; Kidney Tubules; Macrophages; Male; Nephritis; Oligopeptides; Rats; Rats, Wistar | 2010 |
Treatment with N-acetyl-seryl-aspartyl-lysyl-proline prevents experimental autoimmune myocarditis in rats.
Topics: Adaptive Immunity; Animals; Anti-Inflammatory Agents; Autoimmune Diseases; Cell Adhesion Molecules; Chemokines; Cytokines; Disease Models, Animal; Echocardiography; Heart; Immunity, Innate; Male; Myocarditis; Oligopeptides; Rats; Rats, Inbred Lew | 2012 |
N-acetyl-seryl-aspartyl-lysyl-proline ameliorates the progression of renal dysfunction and fibrosis in WKY rats with established anti-glomerular basement membrane nephritis.
Topics: Analysis of Variance; Animals; Anti-Glomerular Basement Membrane Disease; Biopsy, Needle; Blood Chemical Analysis; Blotting, Western; Disease Models, Animal; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Fibrosis; Immunohistochemistry; Injections, Subcutaneous; Kidney Function Tests; Male; Oligopeptides; Probability; Random Allocation; Rats; Rats, Inbred WKY; Reverse Transcriptase Polymerase Chain Reaction; Sensitivity and Specificity; Statistics, Nonparametric; Transforming Growth Factor beta; Urinalysis | 2006 |
Role of N-acetyl-seryl-aspartyl-lysyl-proline in the antifibrotic and anti-inflammatory effects of the angiotensin-converting enzyme inhibitor captopril in hypertension.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antibodies, Monoclonal; Captopril; Disease Models, Animal; Enzyme Activation; Fibrosis; Heart; Hypertension; Inflammation; Kidney; Male; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Oligopeptides; Rats | 2007 |